📊 CTNM Key Takeaways
Investment Thesis
Contineum Therapeutics is a pre-revenue pharmaceutical company with severe cash burn, negative operating cash flow of -$55.3M, and zero revenue generation. The company is rapidly depleting its $75.6M cash position at an unsustainable rate, with only approximately 1.4 years of cash runway remaining based on current burn rates, posing existential risk to operations.
CTNM Strengths
- Substantial cash position of $75.6M provides near-term operational runway
- Strong balance sheet with minimal debt and favorable capital structure (D/E: 0.0x)
- Excellent liquidity position with 27.5x current ratio indicating no near-term solvency concerns
CTNM Risks
- Zero revenue with -$68.1M operating loss indicates no commercial progress or clinical validation
- Negative free cash flow of -$55.5M annually is unsustainable and will deplete cash reserves within 16-17 months
- Development-stage company with no profitability path visible; pharmaceutical development carries high failure risk
- Accelerating net losses (-41.9% YoY deterioration) despite near-term cash availability suggests clinical setbacks
Key Metrics to Watch
- Monthly cash burn rate and runway remaining
- Clinical trial progress and regulatory milestone announcements
- Revenue generation timeline and commercial partnership developments
- Operating cash flow trends and capital efficiency improvements
- Potential dilutive financing activities or capital raises
CTNM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 27.50x current ratio provides a solid financial cushion.
CTNM Profitability Ratios
CTNM vs Healthcare Sector
How Contineum Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTNM Balance Sheet & Liquidity
CTNM 5-Year Financial Trend
5-Year Trend Summary: Contineum Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.18 indicates the company is currently unprofitable.
CTNM Growth Metrics (YoY)
CTNM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$4.8M | $-0.40 |
| Q2 2024 | N/A | -$4.8M | $-0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTNM Capital Allocation
CTNM SEC Filings
Access official SEC EDGAR filings for Contineum Therapeutics, Inc. (CIK: 0001855175)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTNM
What is the AI rating for CTNM?
Contineum Therapeutics, Inc. (CTNM) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTNM's key strengths?
Substantial cash position of $75.6M provides near-term operational runway. Strong balance sheet with minimal debt and favorable capital structure (D/E: 0.0x).
What are the risks of investing in CTNM?
Zero revenue with -$68.1M operating loss indicates no commercial progress or clinical validation. Negative free cash flow of -$55.5M annually is unsustainable and will deplete cash reserves within 16-17 months.
What is CTNM's revenue and growth?
Contineum Therapeutics, Inc. reported revenue of $0.0.
Does CTNM pay dividends?
Contineum Therapeutics, Inc. does not currently pay dividends.
Where can I find CTNM SEC filings?
Official SEC filings for Contineum Therapeutics, Inc. (CIK: 0001855175) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTNM's EPS?
Contineum Therapeutics, Inc. has a diluted EPS of $-2.17.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.